Formulation and evaluation of dorzolamide hydrochloride-loaded nanoparticles as controlled release drug delivery system

Main Article Content

Azza A Hasan


This study aimed to prepare anti-glaucomatous dorzolamide hydrochloride-(Dorzo) loaded nanoparticles as a controlled release system. Eudragit RS 100 (RS) and/or RL 100 (RL) were used in formulations by an opportunely adapted
Quasi-emulsion solvent diffusion technique. The formulations were evaluated in terms of particle size, zeta potential, drug entrapment, and release profile. All formulations showed tiny particle size varying from 114 to 395 nm for RS and
65 to 277 nm for RL. Positive zeta potential was +19 to +32 mV for RS and +23 to +42 mV for RL formulations. It was demonstrated that increasing polymer concentration lead to increase the percentage of drug entrapped in all batches, to
a certain extent (drug: polymer 1:4). Nanoparticles prepared using RL showed lower entrapment efficiency than RS. Incontrast, increasing the stirring rate resulted in an increase in the percentage of Dorzo entrapped. A prolonged drug release was shown by all the formulations. Increasing the polymer concentration caused a decrease in the release rate. Moreover, it was evident that increasing RL content increased the amount of Dorzo released. Dorzo-loaded nanoparticles could represent promising drug ophthalmic carriers, due to small particle size, positive zeta potential, and sustained release profile; hence, expecting prolonged corneal contact time, more therapeutically efficient, decreased frequency of administration per day,
and better patient compliance.


Download data is not yet available.

Article Details

How to Cite
Hasan, A. A. (2014). Formulation and evaluation of dorzolamide hydrochloride-loaded nanoparticles as controlled release drug delivery system. Asian Journal of Pharmaceutics (AJP), 6(1).


Liu X, Rasmussen CA, Gabelt BT, Brandt CR, Kaufman PL. Gene therapy

targeting glaucoma: where are we? Surv Ophthalmol 2009;54:472-86.

Quigley HA, Broman AT. The number of people with glaucoma

worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7.

Maren TH.Carbonic anhydrase: General perspective and advances in

glaucoma research. Drug Dev Res 1987;10:255-76.

Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride,a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther


Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug

delivery. Drug Discov Today 2008;13:144-51.

Araújo J, Gonzalez E, Egea MA, Garcia ML, Souto EB. Nanomedicines for

ocular NSAIDS: safety on drug delivery. Nanomedicine 2009;5:394-40.

Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric

nanoparticulate system: A potential approach for ocular drug delivery.

J Control Release 2009;136:2-13.

Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles

by nanoprecipitation method for ocular drug delivery. Nanomedicine


Dillen K, Weyenberg W, Vandervoort J, Ludwig A. The influence

of the use of viscosifying agents as dispersion media on the drug

release properties from PLGA nanoparticles. Eur J Pharm Biopharm


Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004;7:2342-7.

Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK.

Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for

ocular delivery: Formulation, optimisation and in vitro characterisation.

Eur J Pharm Biopharm 2008;68:513-25.

Araújo J, Vega E, Lopes C, Egea MA, Garcia ML, Souto EB. Effect of

polymer viscosity on physicochemical properties and ocular tolerance

of FB-loaded PLGA nanospheres. Colloids Surf B Biointerfaces

;72:48- 56.

Röhm Pharma Publications, Data Sheet (Into RL/RS-4-e). Darmstadt:

Germany: Röhm GmbH;1990.

Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-

inflammatory activity of ibuprofen carried by an Eudragit RS100

nanoparticle suspension. Ophthalmic Res 2002;34:319-23.

Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. EudragitRS100 nanosuspensions for the ophthalmic controlled delivery of

ibuprofen. Eur J Pharm Sci 2002;16:53-61.

Castelli F, Messina C, Sarpietro MG, Pignatello R, Puglisi G. Flurbiprofen

release from Eudragit RS and RL aqueous nanosuspensions: A kinetic

study by DSC and dialysis experiments. AAPS PharmSciTech 2002;3:1-8.

Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-

loaded acrylate polymer nanosuspensions for ophthalmic application.

Biomaterials 2002;23:3247-55.

Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G.

Preparation and Characterization of Eudragit Retard Nanosuspensions

for the Ocular Delivery of Cloricromene. AAPS PharmSciTech


Adibkia K, Siahi Shadbad MR, Nokhodchi A, Javadzedeh A,

Barzegar- Jalali M, Barar J, et al. Piroxicam nanoparticles for ocular

delivery: physicochemical characterization and implementation in

endotoxin-induced uveitis. J Drug Target 2007;15:407-16.

Adibkia K, Omidi Y, Siahi MR, Javadzadeh AR, Barzegar-Jalali M, Barar J,et al. Inhibition of endotoxin-induced uveitis by methylprednisolone

acetate nanosuspension in rabbits. J Ocul Pharmacol Ther


Das S, Suresh PK. Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to

amphotericin B. Nanomedicine 2011;7:242-7.

Pignatello R, Bucolo C, Puglisi G. Ocular tolerability of Eudragit RS 100

and RL 100 nanosuspensions as carriers for ophthalmic controlled drug

delivery. J Pharm Sci 2002;91:2636-41.

Kawashima Y, Niwa T, Handa T, Takeuchi H, Iwamoto T, Itoh K.

Preparation of controlled-release microspheres of ibuprofen with acrylic

polymers by a novel quasi-emulsion solvent diffusion method. J Pharm

Sci 1989;78:68-72.

Pignatello R, Vandelli MA, Giunchedi P, Puglisi G. Properties of Tolmetin-

loaded Eudragit RL100 and RS100 microparticles prepared by different

techniques. STP Pharma Sci 1997;7:148-57.

Kompella U, Bandi N, Ayalasomayajula S. Poly (lactic acid) nanoparticlesfor sustained release of budesonide. Drug Deliv Technol 2001;1:29-35.

Zimmer AK, Kreuter J. Microspheres and Nps used in ocular drug

delivery systems. Adv Drug Deliv Rev 1995;16:61-73.

Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles:

systematic study of particle size and drug content. Int J Pharm


Nath B, Nath LK, Kumar P. Preparation and in vitro dissolution profile

of zidovudine loaded microspheres made of Eudragit RS 100, RL 100

and their combinations. Acta Pol Pharm 2011;68:409-15.

Kancharla K, Basavaraj BV, Bharath S, Deveswaran R, Madhavan V.

Formulation and evaluation of intragastric floating multiparticulate

system of Aceclofenac. Der Pharm Let 2011;3:238-45.

Benita S. Prevention of topical and ocular oxidative stress by positively

charged submicron emulsion. Biomed Pharmacother 1999;53:193-206.

Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface

charge on indomethacin ocular tissue distribution. Pharm Dev Technol


Pignatello R, Amico D, Chiechio S, Spadaro C, Puglisi G, Giunchedi P.

Preparation and analgesic activity of Eudragit RS100 microparticles

containing diflunisal. Drug Deliv 2001;8:35-45.

Perumal D, Dangor CM, Alcock RS, Hurbans N, Moopanar KR. Effect

of formulation variables on in vitro drug release and micromeritic

properties of modified release ibuprofen microspheres. J Microencapsul


Pignatello R, Ferro M, De Guidi G, Salemi G, Vandelli MA, Guccione S,

et al. Preparation, characterisation and photosensitivity studies of solid

dispersions of diflunisal and Eudragit RS100 and RL100. Int J Pharm


Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allemann E.

Preparation and characterization of sterile sub-200 nm meso-tetra

(4-hydroxylphenyl)porphyrine-loaded nanoparticles for photodynamic

therapy. Eur J Pharm Biopharm 2003;55:115-24.

Dandagi P, Kerur S, Mastiholimath V, Gadad A, Kulkarni A. Polymeric

ocular nanosuspension for controlled release of acyclovir: In vitro

release and ocular distribution. Iran J Pharm Res 2009;8:79-86.

Gaikwad A, Tamizhrasi S, Sorti A, Gavali P, Mehare G. Formulation and

in vitro characterization of polymethacrylic acid nanoparticle containing

Frusemide. Int J Pharm Tech Res 2010;2:300-4.

Bhosale UV, Devi VK. Preparation and In vitro Evaluation of acyclovir

loaded eudragit RLPO nanoparticles as sustained release carriers.

RGUHS J Pharm Sci 2011;1:85-92.

Khopade AJ, Jain NK. Self assembling nanostructures for sustained

ophthalmic drug delivery. Pharmazie 1995;50:812-4.

De Campos A, Sanchez A, Alonso M. Chitosan nanoparticles: a new

vehicle for the improvement of the delivery of drugs to the ocular

surface. Application to cyclosporin A. Int J Pharm 2001;224:159-68.

Romero-Cano M, Vinceent B. Controlled Release of 4-nitroanisole from

poly (lactic acid) nanoparticles. J Control Release 2002;82:127-35.

Bodmeier R, Chen H. Preparation and characterization of microspheres

containing the anti-inflammatory agents, Indomethacin, ibuprofen and

kitoprofen. J Control Release 1989;10:167-75.

Pignatello R, Consoli P, Pulgisi G. In vitro release kinetics of Tolmetin from

tabletted Eudragit microparticles. J Microencapsul 2000;17:373- 83.